Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
Condition: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Interventions: Drug: Dasatinib; Other: Laboratory Biomarker Analysis; Drug: Nilotinib; Drug: Ruxolitinib Phosphate Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Leukemia | Nilotinib | Tasigna